For more information, refer to Paxlovid: A Guide for B.C. Pharmacists
Generic name |
nirmatrelvir/ritonavir (Paxlovid™) |
|
---|---|---|
Strength |
300/100 mg (eGFR greater than or equal to 60 mL/min); 150/100 mg (eGFR 30-59 mL/min) |
|
Form |
tablet |
Criteria |
---|
Nirmatrelvir/ritonavir (Paxlovid™) is indicated for use in patients 18 years and older with mild/moderate COVID-19 infection who are at risk for disease progression*. Paxlovid™ is prescribed using a Paxlovid™ prescription form. Nirmatrelvir/ritonavir (Paxlovid™) is covered under PharmaCare’s Plan Z (Assurance Plan) as a regular benefit. Exceptional Plan Z coverage of Paxlovid is available for any patient receiving treatment in B.C.. They may be in the wait period for MSP, or they may live in a different province or country (see Special Notes). |
*See Practice Tool #1: Clinician Assessment for details on risk disease progression and definition of vaccine status. See Practice Tool #2 for CEV criteria details. http://www.bccdc.ca/health-professionals/clinical-resources/covid-19-care/treatments
When prescribing Paxlovid, use the below Rx form. This provides pharmacies with essential information and ensures this medication is dispensed quickly, so that patients can begin their treatment within the clinical time frame.